Safety, feasibility, and short-term follow-up of drug-eluting stent placement in the intracranial and extracranial circulation

Stroke. 2006 Oct;37(10):2562-6. doi: 10.1161/01.STR.0000242481.38262.7b. Epub 2006 Sep 7.

Abstract

Background and purpose: The use of bare metal stents to treat symptomatic intracranial stenosis may be associated with significant restenosis rates. The advent of drug-eluting stents (DESs) in the coronary circulation has resulted in a reduction of restenosis rates. We report our technical success rate and short-term restenosis rates after stenting with DESs in the intracranial and extracranial circulation.

Methods: This study was a retrospective review of the period between April 1, 2004, and April 15, 2006, of 59 patients with 62 symptomatic intracranial or extracranial atherosclerotic lesions at 2 medical centers (University of Pittsburgh and Borgess Medical Center).

Results: The mean age of our cohort was 61+/-12 years. The location of the 62 lesions was as follows: extracranial vertebral artery 31 (50%), intracranial vertebral artery or basilar artery 18 (29%), extracranial internal carotid artery (ICA) near the petrous bone 5 (8%), and intracranial ICA 8 (13%). There were 2 (3%) periprocedural complications: 1 non-flow-limiting dissection and 1 disabling stroke. Fifty vessels were available for follow-up angiography or computed tomography angiography at a median time of 4.0+/-2 months. A total of 2 of 36 extracranial stents (7%) and 1 of 26 intracranial stents (5%) were found to have restenosis > or = 50% at follow-up.

Conclusions: This report demonstrates that DES delivery in the intracranial and extracranial circulation is technically feasible. A small percentage of patients developed short-term in-stent restenosis. Longer-term follow-up is required in the setting of a prospective study to determine the late restenosis rates for DESs in comparison with bare metal stents.

Publication types

  • Comparative Study
  • Evaluation Study
  • Multicenter Study

MeSH terms

  • Anticoagulants / therapeutic use
  • Aortic Dissection / etiology
  • Calcinosis / therapy
  • Carotid Artery, External*
  • Carotid Artery, Internal*
  • Carotid Stenosis / prevention & control
  • Carotid Stenosis / therapy*
  • Catheterization
  • Cohort Studies
  • Drug Evaluation
  • Drug Implants
  • Feasibility Studies
  • Female
  • Follow-Up Studies
  • Humans
  • Ischemic Attack, Transient / drug therapy
  • Ischemic Attack, Transient / prevention & control
  • Ischemic Attack, Transient / therapy
  • Male
  • Middle Aged
  • Organ Specificity
  • Paclitaxel / administration & dosage
  • Paclitaxel / adverse effects
  • Paclitaxel / therapeutic use*
  • Recurrence
  • Retrospective Studies
  • Sirolimus / administration & dosage
  • Sirolimus / adverse effects
  • Sirolimus / therapeutic use*
  • Stents / adverse effects
  • Stents / statistics & numerical data*
  • Stroke / etiology
  • Vertebrobasilar Insufficiency / prevention & control
  • Vertebrobasilar Insufficiency / therapy*

Substances

  • Anticoagulants
  • Drug Implants
  • Paclitaxel
  • Sirolimus